31685-38-8

Basic information

• Product Name: 2-(1-adamantyl)propanol
• Synonyms: 2-(1-adamantyl)propanol;3-(1-Adamantyl)propan-1-ol
• CAS NO: 31685-38-8
• Molecular Formula: C₁₃H₂₂O
• Molecular Weight: 194.31
• Mol File: 31685-38-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 287.4 °C at 760 mmHg
• Flash Point: 134.8 °C
• Appearance: /
• Density: 1.045 g/cm³
• Vapor Pressure: 0.000279mmHg at 25°C
• Refractive Index: 1.532
• CAS DataBase Reference: 2-(1-adamantyl)propanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-adamantyl)propanol(31685-38-8)
• EPA Substance Registry System: 2-(1-adamantyl)propanol(31685-38-8)

Safety Data

• Hazardous Substances Data: 31685-38-8(Hazardous Substances Data)

Usage

General Description

2-(1-adamantyl)propanol, also known as ADAPTOL, is a chemical compound that belongs to the class of alcohols. It is a derivative of adamantane and is commonly used as a central nervous system depressant with anxiolytic properties. ADAPTOL has demonstrated effectiveness in reducing anxiety and tension, and it is often used in the treatment of anxiety disorders and other conditions related to stress and tension. The chemical structure of 2-(1-adamantyl)propanol gives it unique pharmacological properties, making it a promising candidate for the development of new anxiolytic medications. Additionally, it has minimal sedative effects and is well tolerated, making it a favorable option for patients who require long-term treatment for anxiety.

InChI:InChI=1/C13H22O/c14-3-1-2-13-7-10-4-11(8-13)6-12(5-10)9-13/h10-12,14H,1-9H2

Upstream product

• 26831-48-1 2-(adamantan-1-yl)ethyl-4-methylbenzenesulfonate 
• 4942-47-6 (adamant-1-yl)-acetic acid 
• 6240-11-5 2-(adamant-1-yl)ethanol 
• 29542-59-4 methyl 3-(adamantan-1-yl)propanoate 
• 50-00-0 formaldehyd 
• 773-37-5 1-(2-bromo-ethyl)-adamantane 
• 136258-27-0 trans-3-(1-adamantyl)acrylic acid 
• 113249-58-4 trans-3-(1-adamantyl)acrylic acid 
• 16269-16-2 3-(1-adamantyl)propanoic acid 
• 711-01-3 methyl adamantane-1-carboxylate 
• 770-71-8 1-adamantanemethanol 
• 768-95-6 1-adamanthanol 
• 2094-74-8 1-Adamantanecarbaldehyde 
• 828-51-3 1-Adamantanecarboxylic acid 

Downstream Products

• 1305348-89-3 methyl 4-[(1E)-4-(adamant-1-yl)but-1-en-1-yl]benzoate 
• 1305348-90-6 4-[(1E)-4-(adamant-1-yl)but-1-en-1-yl]benzoic acid 
• 1305348-91-7 4-[4-(adamant-1-yI)butyl]benzoic acid 
• 1305348-93-9 C₂₂H₂₈N₂O 
• 1305348-92-8 ethyl {4-[4-(adamant-1-yl)butyl]phenyl}acetate 
• 1383850-43-8 di[3-(1-adamantyl)propyl] tosyloxymethylphosphonate 

Relevant articles and documents

Synthesis and Structure-Activity Relationships of Ring-Opened Bengamide Analogues against Methicillin-Resistant Staphylococcus aureus?

Methicillin-resistant Staphylococcus aureus (MRSA) has become a major threat on public health because of the increase of clinically isolated strains that exhibit resistance to many antibiotics. Therefore, development of new antibiotics for the treatment of MRSA infection is a sustained challenge. We have previously identified a ring-opened bengamide analogue L472-2 that displays moderate activity against the growth of S. aureus. In our previous work, we started from L472-2 and identified a class of analogues containing alkynyl groups which have the potential to activate SaClpP activity but moderate antibacterial activity. Herein, we focused on the antibacterial activity of L472-2, and a novel series of ring-opened bengamide analogues were synthesized and their activities were evaluated against MRSA. By conducting a compact analysis of the structure-activity relationships (SAR) of these analogues, we found that an adamantane ethanol ester bengamide 2j showed excellent antibacterial activity towards six S. aureus strains, including MRSA, while it does not activate ClpP. Therefore, these bengamide analogues represent a new class of candidates that suppress MRSA viability.

HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF FUNGAL INFECTIONS

Described are bridged compounds of the formula (I), their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. The invention relates to compositions and methods to treat fungal infection. These compounds are selective HDAC inhibitors that act as inherent antifungal compounds or enhance the activity of other antifungal compounds such as azoles.